Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Immunovia AB ( (SE:IMMNOV) ) is now available.
Immunovia AB has announced a rights issue of shares valued at approximately SEK 100 million, approved by the company’s board and shareholders. The rights issue is fully covered by subscription undertakings and guarantee commitments, with key board members contributing to the subscription. This move aims to strengthen Immunovia’s financial position as it continues to focus on early detection of pancreatic cancer, potentially impacting its market presence and stakeholder confidence.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes testing to detect proteins and blood-based antibodies indicating pancreatic cancer, collaborating with healthcare providers and experts to make these tests available to high-risk individuals.
Average Trading Volume: 14,260,423
Technical Sentiment Signal: Sell
Current Market Cap: SEK124.5M
See more data about IMMNOV stock on TipRanks’ Stock Analysis page.